Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Shock ; 57(2): 205-211, 2022 02 01.
Article in English | MEDLINE | ID: mdl-34812186

ABSTRACT

BACKGROUND: Innate immune dysregulation may contribute to age-related differences in outcomes among critically ill adults. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is an important innate immune marker with prognostic value in sepsis, but age-related differences have not been studied. METHODS: This was a prospective cohort from a large tertiary care hospital enrolling adults from both medical and trauma-surgical intensive care units (ICUs). Plasma sTREM-1 was measured in participants within 24 h of ICU admission. We analyzed associations between age (≤50 and >50 years) and sTREM-1 using linear regression. We then examined associations between sTREM-1 and both 28-day mortality and persistent organ dysfunction (defined as need for dialysis, vasopressors, or invasive mechanical ventilation) 7 days following admission using relative risk regression. RESULTS: Of 231 critically ill adults, older patients (n = 122) had higher prevalence of chronic disease and sepsis on enrollment than younger patients, but acute illness severity was similar. Age over 50 was associated with 27% higher sTREM-1 concentrations (95% CI 6%-53%), adjusted for sex and Charlson comorbidity index (CCI). Two-fold higher sTREM-1 was associated with 2.42-fold higher risk for mortality (95% CI 1.57, 3.73) and 1.86-fold higher risk for persistent organ dysfunction (95% CI 1.45, 2.39), adjusted for sex, CCI, and age. CONCLUSIONS: sTREM-1 was elevated among critically ill older adults, and strongly associated with both death and persistent organ dysfunction. Immune responses associated with sTREM-1 may contribute to age-related differences in ICU outcomes, warranting further study as a potential therapeutic target in older adults.


Subject(s)
Sepsis/blood , Sepsis/immunology , Triggering Receptor Expressed on Myeloid Cells-1/blood , Adult , Age Factors , Aged , Cohort Studies , Critical Illness , Female , Humans , Male , Middle Aged , Prospective Studies , Triggering Receptor Expressed on Myeloid Cells-1/physiology
2.
Shock ; 57(2): 246-255, 2022 02 01.
Article in English | MEDLINE | ID: mdl-34864782

ABSTRACT

INTRODUCTION: Triggering receptor expressed on myeloid cells-1 (TREM-1) has important implications in sepsis and inflammation and is a novel receptor for extracellular cold-inducible RNA-binding protein (eCIRP). We hypothesize that the inhibition of TREM-1 via its interaction with eCIRP by novel peptide inhibitor M3 or knockout gene will attenuate the inflammation and injury associated with severe hepatic ischemia/reperfusion (I/R). METHODS: Wild-type (WT) C57BL/6 and TREM-1-/- mice underwent 60 min of 70% hepatic ischemia, with 24 h of reperfusion. Additionally, WT mice underwent hepatic I/R and were treated with M3 (10 mg/kg body weight) or vehicle (normal saline) at the start of reperfusion. Blood and ischemic liver tissues were collected, and analysis was performed using enzymatic assays, enzyme-linked immunosorbent assay, reverse-transcription quantitative polymerase chain reaction, and pathohistology techniques. For survival surgery, mice additionally underwent resection of non-ischemic lobes of the liver and survival was monitored for 10 days. RESULTS: There was an increase in serum levels of tissue markers including aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase as well as cytokine levels (IL-6) and histological scoring of hematoxylin and eosin sections in WT I/R mice. These markers decreased substantially in TREM-1-/- mice. Additionally, neutrophil infiltration markers and markers of local inflammation (myeloperoxidase, macrophage inflammatory protein-2, cyclooxygenase-2) were attenuated in TREM-1-/- mice. Similarly, we show a significant decrease in injury and inflammation markers with M3 treatment. Additionally, we demonstrate decreased apoptosis with TREM-1 inhibition. Finally, M3 treatment improved the survival rate from 42% to 75% after hepatic I/R. CONCLUSION: TREM-1 is an important eCIRP receptor in the inflammatory response of hepatic I/R, and deficiency of TREM-1 via knockout gene or peptide inhibition attenuated liver injury and inflammation, and improved survival. Inhibition of the TREM-1 and eCIRP interaction in hepatic I/R may have important therapeutic potential.


Subject(s)
Inflammation/etiology , Liver/blood supply , RNA-Binding Proteins/physiology , Reperfusion Injury/mortality , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Animals , Mice , Mice, Inbred C57BL , Survival Rate
3.
Placenta ; 115: 97-105, 2021 11.
Article in English | MEDLINE | ID: mdl-34598084

ABSTRACT

INTRODUCTION: Excessive activation of maternal systemic inflammation is one of the underlying causes of pathology during the disease course of preeclampsia (PE). The triggering receptor expressed on myeloid cells-1 (TREM-1) participates in the development and persistence of inflammation. We hypothesized that dysregulated TREM-1 may be involved in the pathogenesis of PE by promoting the secretion of trophoblastic pro-inflammatory cytokines that augment inflammation. METHODS: The localization of TREM-1 in placenta and the extravillous trophoblast cell line (TEV-1) was determined by immunohistochemical staining. The expression level of TREM-1 and pro-inflammatory cytokines in placentas were compared between normal pregnancies and PE. We used lipopolysaccharide (LPS) to simulate trophoblastic inflammation. TEV-1 cells were transfected with TREM-1 plasmid and si-TREM-1 respectively, and then were incubated with LPS. The expression levels of pro-inflammatory cytokines and key molecules featured in nuclear transcription factor-kappaB (NF-κB) pathway were detected. Transwell assays were used to detect the effects of TREM-1 on cell migration and invasion. RESULTS: TREM-1 was localized on both villous trophoblasts (VTs) and extravillous trophoblasts (EVTs). TREM-1 and pro-inflammatory cytokines were up-regulated in preeclamptic placenta. Overexpression of TREM-1 promoted the activation of NF-κB pathway and the release of pro-inflammatory factors induced by LPS, and enhanced migration and invasion of TEV-1 cells. Inhibition of TREM-1 significantly attenuated LPS-induced effects and suppressed migration and invasion. DISCUSSION: This study suggested that TREM-1 was up-regulated in PE, and may promote the production of downstream inflammatory factors by activating NF-κB pathway in trophoblastic cells, thus exerting pro-inflammatory effects in the pathogenesis of PE.


Subject(s)
Inflammation/physiopathology , NF-kappa B/physiology , Pre-Eclampsia/physiopathology , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Trophoblasts/physiology , Adult , Cell Line, Transformed , Female , Humans , Interleukins/genetics , Lipopolysaccharides/pharmacology , Placenta/chemistry , Pregnancy , RNA, Messenger/analysis , Transfection , Triggering Receptor Expressed on Myeloid Cells-1/analysis , Triggering Receptor Expressed on Myeloid Cells-1/genetics , Trophoblasts/chemistry , Trophoblasts/drug effects , Tumor Necrosis Factor-alpha/genetics
4.
Mediators Inflamm ; 2021: 2327721, 2021.
Article in English | MEDLINE | ID: mdl-34135689

ABSTRACT

BACKGROUND: Triggering receptor expressed on myeloid cells-1 (TREM-1) controls the mobilization of inflammatory cells in response to injury and consequently enhances liver damage. LR12 is a TREM-1 inhibitory peptide. However, the role of LR12 in acute liver failure (ALF) has remained elusive. This study was aimed at indicating whether LR12 could promote liver repair in mice with thioacetamide- (TAA-) induced ALF. METHODS: BALB/c mice were intraperitoneally injected with TAA, followed by intravenous injection of LR12. Damage and regeneration of the liver were assessed. LO2 cells and macrophages were used to assess the therapeutic effects of LR12. RESULTS: Mice treated with TAA for 24 h developed ALF, while liver inflammation was alleviated after LR12 treatment. Moreover, LR12 promoted hepatocyte regeneration in mice with TAA-induced ALF. In vitro, the supernatant from TAA+LR12-treated macrophages promoted the proliferation of LO2 cells. Cytokine protein microarray analysis suggested that LR12 promoted the secretion of C-C chemokine ligand 20 (CCL20) from macrophages. Besides, neutralization of CCL20 blocked the effects of LR12, thus inhibited the proliferation of LO2 cells in vitro, aggregated the liver inflammation, and restrained hepatocyte regeneration in ALF mice in vivo. Furthermore, we also found that LR12 activated the p38 mitogen-activated protein kinase (MAPK) pathway in hepatocytes through promoting the secretion of CCL20 from macrophages. CONCLUSIONS: LR12 could improve the resolution of inflammation and liver regeneration in mice with TAA-induced ALF by promoting the secretion of CCL20 from macrophages and activating the p38 MAPK pathway. Therefore, LR12 could be an attractive therapeutic target for the treatment of ALF.


Subject(s)
Inflammation/drug therapy , Liver Failure, Acute/drug therapy , Liver Regeneration , Liver/physiology , Oligopeptides/chemistry , Peptides/chemistry , Thioacetamide , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Animals , Cell Line , Cell Proliferation , Cytokines/metabolism , Enzyme-Linked Immunosorbent Assay , Hepatocytes/metabolism , Humans , MAP Kinase Signaling System , Macrophages/metabolism , Male , Mice , Mice, Inbred BALB C , Microscopy, Confocal , Treatment Outcome , p38 Mitogen-Activated Protein Kinases/metabolism
5.
Cell Mol Immunol ; 18(2): 452-460, 2021 02.
Article in English | MEDLINE | ID: mdl-33420354

ABSTRACT

During sepsis, neutrophil activation induces endothelial cell (EC) dysfunction partly through neutrophil extracellular trap (NET) release. The triggering receptor expressed on myeloid cell-1 (TREM-1) is an orphan immune receptor that amplifies the inflammatory response mediated by Toll-like receptor-4 (TLR4) engagement. Although the key role of TLR4 signaling in NETosis is known, the role of TREM-1 in this process has not yet been investigated. Here, we report that TREM-1 potentiates NET release by human and murine neutrophils and is a component of the NET structure. In contrast, pharmacologic inhibition or genetic ablation of TREM-1 decreased NETosis in vitro and during experimental septic shock in vivo. Moreover, isolated NETs were able to activate ECs and impair vascular reactivity, and these deleterious effects were dampened by TREM-1 inhibition. TREM-1 may, therefore, constitute a new therapeutic target to prevent NETosis and associated endothelial dysfunction.


Subject(s)
Endothelium, Vascular/immunology , Extracellular Traps/physiology , Neutrophils/immunology , Sepsis/prevention & control , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Adolescent , Adult , Aged , Animals , Endothelium, Vascular/metabolism , Healthy Volunteers , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Sepsis/immunology , Sepsis/pathology , Signal Transduction , Triggering Receptor Expressed on Myeloid Cells-1/antagonists & inhibitors , Young Adult
6.
FASEB J ; 34(7): 9771-9786, 2020 07.
Article in English | MEDLINE | ID: mdl-32506691

ABSTRACT

Extracellular cold-inducible RNA-binding protein (eCIRP) is a damage-associated molecular pattern (DAMP). Intercellular adhesion molecule-1 (ICAM-1) expressing neutrophils produce excessive amounts of neutrophil extracellular traps (NETs). We reveal that eCIRP generates ICAM-1+ neutrophils through triggering receptor expressed on myeloid cells-1 (TREM-1) and the ICAM-1+ neutrophils involve Rho GTPase to promote NETosis. Treatment of BMDN with rmCIRP increased the frequency of ICAM-1+ BMDN, while rmCIRP-treated TREM-1-/- BMDN or pretreatment of BMDN with TREM-1 inhibitor LP17 significantly decreased the frequency of ICAM-1+ neutrophils. The frequencies of ICAM-1+ neutrophils in blood and lungs were markedly decreased in rmCIRP-injected mice or septic mice treated with LP17. Coculture of ICAM-1-/- neutrophils or wild-type (WT) neutrophils with WT macrophages in the presence of a peptidylarginine deiminase 4 (PAD4) inhibitor reduced TNF-α and IL-6 compared to WT neutrophils treated with rmCIRP. Treatment of ICAM-1-/- neutrophils with rmCIRP resulted in reduced quantities of NETs compared to WT rmCIRP-treated neutrophils. Treatment of BMDN with rmCIRP-induced Rho activation, while blockade of ICAM-1 significantly decreased Rho activation. Inhibition of Rho significantly decreased rmCIRP-induced NET formation in BMDN. TREM-1 plays a critical role in the eCIRP-mediated increase of ICAM-1 expression in neutrophils, leading to the increased NET formation via Rho activation to exaggerate inflammation.


Subject(s)
Extracellular Traps/immunology , Intercellular Adhesion Molecule-1/metabolism , Neutrophils/immunology , RNA-Binding Proteins/metabolism , Sepsis/pathology , Triggering Receptor Expressed on Myeloid Cells-1/physiology , rho GTP-Binding Proteins/metabolism , Animals , Disease Models, Animal , Extracellular Traps/metabolism , Inflammation/etiology , Inflammation/metabolism , Inflammation/pathology , Intercellular Adhesion Molecule-1/genetics , Macrophages/immunology , Macrophages/metabolism , Macrophages/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Neutrophils/metabolism , Neutrophils/pathology , RNA-Binding Proteins/genetics , Sepsis/etiology , Sepsis/metabolism , rho GTP-Binding Proteins/genetics
7.
Cells ; 8(10)2019 09 21.
Article in English | MEDLINE | ID: mdl-31546668

ABSTRACT

Alterations in Triggering Receptors Expressed on Myeloid cells (TREM-1/2) are bound to a variety of infectious, sterile inflammatory, and degenerative conditions, ranging from inflammatory bowel disease (IBD) to neurodegenerative disorders. TREMs are emerging as key players in pivotal mechanisms often concurring in IBD and neurodegeneration, namely microbiota dysbiosis, leaky gut, and inflammation. In conditions of dysbiosis, compounds released by intestinal bacteria activate TREMs on macrophages, leading to an exuberant pro-inflammatory reaction up to damage in the gut barrier. In turn, TREM-positive activated macrophages along with inflammatory mediators may reach the brain through the blood, glymphatic system, circumventricular organs, or the vagus nerve via the microbiota-gut-brain axis. This leads to a systemic inflammatory response which, in turn, impairs the blood-brain barrier, while promoting further TREM-dependent neuroinflammation and, ultimately, neural injury. Nonetheless, controversial results still exist on the role of TREM-2 compared with TREM-1, depending on disease specificity, stage, and degree of inflammation. Therefore, the present review aimed to provide an update on the role of TREMs in the pathophysiology of IBD and neurodegeneration. The evidence here discussed the highlights of the potential role of TREMs, especially TREM-1, in bridging inflammatory processes in intestinal and neurodegenerative disorders.


Subject(s)
Inflammatory Bowel Diseases/genetics , Neurodegenerative Diseases/genetics , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Animals , Blood-Brain Barrier/physiology , Disease Susceptibility , Dysbiosis/complications , Dysbiosis/genetics , Dysbiosis/immunology , Dysbiosis/psychology , Gastrointestinal Microbiome/physiology , Humans , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/microbiology , Inflammatory Bowel Diseases/psychology , Membrane Glycoproteins/genetics , Membrane Glycoproteins/physiology , Neurodegenerative Diseases/immunology , Neurodegenerative Diseases/microbiology , Receptors, Immunologic/genetics , Receptors, Immunologic/physiology , Risk Factors , Triggering Receptor Expressed on Myeloid Cells-1/genetics
8.
Eur Rev Med Pharmacol Sci ; 22(21): 7533-7542, 2018 11.
Article in English | MEDLINE | ID: mdl-30468503

ABSTRACT

OBJECTIVE: The study aimed to explore the effects of p-cresyl sulfate (PCS) of damaging vascular endothelial cells and promoting the formation of atherosclerosis in mice. MATERIALS AND METHODS: The apolipoprotein E (ApoE)-/- mice were fed normally and with a high-fat diet; the ApoE-/- mice fed with high-fat diet were divided into two groups and treated with blank control and PCS, respectively. The aortic arch in each group was taken and underwent the oil red O staining, and the serum PCS content in each group was detected. The basic components of plaque were observed, including foam cells, lipid deposition, and cholesterol crystal. Moreover, human umbilical vein endothelial cells were cultured and divided into control group, PCS treatment group (PCS), PCS treatment with TLR4 overexpression group (PCS+TLR4+), and PCS treatment with TLR4 knock-out group (PCS+TLR4-). The degree of endothelial cell damage was detected using a cluster of differentiation CD42b-/CD31+ endothelial microparticles (EMPs), and expressions of Toll-like receptor 4 (TLR4), triggering receptor expressed on myeloid cells-1 (TREM-1), phosphorylated-endothelial nitric oxide synthase (p-eNOS), and tumor necrosis factor-α (TNF-α) in cells were detected via Polymerase Chain Reaction (PCR) and Western blotting. RESULTS: The serum PCS concentration in high-fat ApoE-/- mice was increased, and the aortic arch sections of ApoE-/- mice treated with PCS displayed the evident atherosclerotic plaques. Experimental results of human umbilical vein endothelial cells showed that the activity of human umbilical vein endothelial cells treated with PCS declined, the expression levels of TLR4, TREM-1, and TNF-α were increased, while that of p-eNOS was decreased. After the TLR4 knockout, the above effects of PCS were reversed. CONCLUSIONS: PCS damages vascular endothelial cells through TRL4/TREM-1, thereby accelerating the formation of atherosclerosis.


Subject(s)
Atherosclerosis/chemically induced , Cresols/toxicity , Human Umbilical Vein Endothelial Cells/drug effects , Sulfuric Acid Esters/toxicity , Toll-Like Receptor 4/physiology , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Animals , Cells, Cultured , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Mice , Nitric Oxide Synthase Type III/metabolism , Tumor Necrosis Factor-alpha/metabolism
9.
Sci Rep ; 8(1): 8223, 2018 05 29.
Article in English | MEDLINE | ID: mdl-29844416

ABSTRACT

Triggering receptor expressed on myeloid cells 1 (TREM-1) amplifies inflammatory responses and is upregulated during sepsis and pulmonary infection. The association between serum soluble TREM-1 (sTREM-1) level and pulmonary tuberculosis (PTB) disease deserves investigation. In the present study, patients with PTB, latent TB infection (LTBI), and non-TB, non-LTBI subjects were prospectively enrolled and serum levels of sTREM-1, sTREM-2, and C-reactive protein (CRP) were measured. We correlated serum biomarkers and clinical presentations and treatment outcomes of PTB cases. We also utilized immunohistochemistry (IHC) to visualize TREM-1-expressing cells in lung tissues from PTB patients. A total of 86 PTB, 41 LTBI, and 20 non-TB, non-LTBI subjects were enrolled. Serum levels of sTREM-1 and CRP significantly increased in PTB patients; these higher serum levels were correlated with more advanced involvement in chest films and higher bacteria burden in sputum. In multivariate analysis, serum levels of sTREM-1 >260 pg/mL and CRP >2.6 mg/L were independent predictors for on-treatment mortality. Abundant TREM-1-expressing macrophages were identified in lung tissues from PTB samples. In conclusion, serum levels of sTREM-1 correlated with disease severity and treatment outcomes in PTB patients.


Subject(s)
Triggering Receptor Expressed on Myeloid Cells-1/physiology , Tuberculosis, Pulmonary/blood , Aged , Aged, 80 and over , Antitubercular Agents/therapeutic use , Biomarkers/blood , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Lung/metabolism , Male , Middle Aged , Treatment Outcome , Triggering Receptor Expressed on Myeloid Cells-1/blood , Triggering Receptor Expressed on Myeloid Cells-1/metabolism , Tuberculosis, Pulmonary/drug therapy
10.
Sci Rep ; 7(1): 14870, 2017 11 01.
Article in English | MEDLINE | ID: mdl-29093489

ABSTRACT

Triggering receptor expressed on myeloid cells-1 (TREM-1) is a potent amplifier of pro-inflammatory innate immune responses. Increasing evidence suggests a role for TREM-1 not only in acute pathogen-induced reactions but also in chronic and non-infectious inflammatory disorders, including various types of cancer. Here, we demonstrate that genetic deficiency in Trem1 protects from colorectal cancer. In particular, Trem1 -/- mice exhibited reduced tumor numbers and load in an experimental model of inflammation-driven tumorigenesis. Gene expression analysis of Trem1 -/- versus Trem1 +/+ tumor tissue demonstrated distinct immune signatures. Whereas Trem1 -/- tumors showed an increased abundance of transcripts linked to adaptive immunity, Trem1 +/+ tumors were characterized by overexpression of innate pro-inflammatory genes associated with tumorigenesis. Compared to adjacent tumor-free colonic mucosa, expression of Trem1 was increased in murine and human colorectal tumors. Unexpectedly, TREM-1 was not detected on tumor-associated Ly6C- MHC class II+ macrophages. In contrast, TREM-1 was highly expressed by tumor-infiltrating neutrophils which represented the predominant myeloid population in Trem1 +/+ but not in Trem1 -/- tumors. Collectively, our findings demonstrate a clear role of TREM-1 for intestinal tumorigenesis and indicate TREM-1-expressing neutrophils as critical players in colorectal tumor development.


Subject(s)
Carcinogenesis/drug effects , Intestinal Neoplasms/pathology , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Animals , Colorectal Neoplasms/etiology , Colorectal Neoplasms/metabolism , Humans , Immunity, Innate , Inflammation , Intestinal Neoplasms/etiology , Intestinal Neoplasms/metabolism , Mice , Neutrophils/metabolism , Triggering Receptor Expressed on Myeloid Cells-1/deficiency , Triggering Receptor Expressed on Myeloid Cells-1/genetics
11.
PLoS One ; 12(11): e0188232, 2017.
Article in English | MEDLINE | ID: mdl-29141025

ABSTRACT

Eucalyptus oil (EO) used in traditional medicine continues to prove useful for aroma therapy in respiratory ailments; however, there is a paucity of information on its mechanism of action and active components. In this direction, we investigated EO and its dominant constituent 1,8-cineole (eucalyptol) using the murine lung alveolar macrophage (AM) cell line MH-S. In an LPS-induced AM inflammation model, pre-treatment with EO significantly reduced (P ≤0.01or 0.05) the pro-inflammatory mediators TNF-α, IL-1 (α and ß), and NO, albeit at a variable rate and extent; 1,8-cineole diminished IL-1 and IL-6. In a mycobacterial-infection AM model, EO pre-treatment or post-treatment significantly enhanced (P ≤0.01) the phagocytic activity and pathogen clearance. 1,8-cineole also significantly enhanced the pathogen clearance though the phagocytic activity was not significantly altered. EO or 1,8-cineole pre-treatment attenuated LPS-induced inflammatory signaling pathways at various levels accompanied by diminished inflammatory response. Among the pattern recognition receptors (PRRs) involved in LPS signaling, the TREM pathway surface receptor (TREM-1) was significantly downregulated. Importantly, the pre-treatments significantly downregulated (P ≤0.01) the intracellular PRR receptor NLRP3 of the inflammasome, which is consistent with the decrease in IL-1ß secretion. Of the shared downstream signaling cascade for these PRR pathways, there was significant attenuation of phosphorylation of the transcription factor NF-κB and p38 (but increased phosphorylation of the other two MAP kinases, ERK1/2 and JNK1/2). 1,8-cineole showed a similar general trend except for an opposite effect on NF-κB and JNK1/2. In this context, either pre-treatment caused a significant downregulation of MKP-1 phosphatase, a negative regulator of MAPKs. Collectively, our results demonstrate that the anti-inflammatory activity of EO and 1,8-cineole is modulated via selective downregulation of the PRR pathways, including PRR receptors (TREM-1 and NLRP3) and common downstream signaling cascade partners (NF-κB, MAPKs, MKP-1). To our knowledge, this is the first report on the modulatory role of TREM-1 and NLRP3 inflammasome pathways and the MAPK negative regulator MKP-1 in context of the anti-inflammatory potential of EO and its constituent 1,8-cineole.


Subject(s)
Cyclohexanols/pharmacology , Dual Specificity Phosphatase 1/physiology , Eucalyptus/chemistry , Inflammation/immunology , Macrophages, Alveolar/drug effects , Monoterpenes/pharmacology , Mycobacterium Infections/immunology , NF-kappa B/physiology , NLR Family, Pyrin Domain-Containing 3 Protein/physiology , Plant Oils/chemistry , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Animals , Colony Count, Microbial , Dose-Response Relationship, Drug , Eucalyptol , Macrophages, Alveolar/immunology , Macrophages, Alveolar/metabolism , Mice , Mycobacterium smegmatis/isolation & purification , Phagocytosis/drug effects
12.
Sci Rep ; 6: 28556, 2016 06 22.
Article in English | MEDLINE | ID: mdl-27328755

ABSTRACT

TREM1 (Triggering Receptor Expressed on Myeloid Cells 1) is a pro-inflammatory receptor expressed by phagocytes, which can also be released as a soluble molecule (sTREM1). The roles of TREM1 and sTREM1 in liver infection and inflammation are not clear. Here we show that patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection manifest elevated serum levels of sTREM1. In mice, experimental viral hepatitis induced by infection with Lymphocytic Choriomeningitis Virus (LCMV)-WE was likewise associated with increased sTREM1 in serum and urine, and with increased TREM1 and its associated adapter molecule DAP12 in the liver. Trem1-/- mice showed accelerated clearance of LCMV-WE and manifested attenuated liver inflammation and injury. TREM1 expression in the liver of wild-type mice was mostly confined to infiltrating neutrophils, which responded to LCMV by secretion of CCL2 and TNF-α, and release of sTREM1. Accordingly, the production of CCL2 and TNF-α was decreased in the livers of LCMV-infected Trem1-/- mice, as compared to LCMV-infected wildtype mice. These findings indicate that TREM1 plays a role in viral hepatitis, in which it seems to aggravate the immunopathology associated with viral clearance, mainly by increasing the inflammatory activity of neutrophils.


Subject(s)
Hepatitis, Viral, Animal/immunology , Hepatitis, Viral, Animal/pathology , Neutrophils/immunology , Triggering Receptor Expressed on Myeloid Cells-1/deficiency , Adult , Aged , Animals , Arenaviridae Infections/immunology , Arenaviridae Infections/pathology , Case-Control Studies , Chemokine CCL2/biosynthesis , Female , Hepatitis B/blood , Hepatitis B/immunology , Hepatitis C/blood , Hepatitis C/immunology , Humans , Inflammation/pathology , Liver/immunology , Liver/pathology , Lymphocytic choriomeningitis virus , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Neutrophils/pathology , Triggering Receptor Expressed on Myeloid Cells-1/blood , Triggering Receptor Expressed on Myeloid Cells-1/genetics , Triggering Receptor Expressed on Myeloid Cells-1/physiology , Tumor Necrosis Factor-alpha/biosynthesis , Young Adult
14.
Aging Clin Exp Res ; 28(4): 775-9, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26497826

ABSTRACT

BACKGROUND: Aging of the innate immune system can result in a wide array of decreasing biological function. AIM: We investigated differences between young and old mice in the expression of the pattern-recognition receptors (PRRs). METHODS: mRNA levels for PRRs were quantified and compared in peritoneal fluid and spleens from old (36 months old) and young (1 month old) Wistar white rats (n = 8/group) using real-time reverse transcription-polymerase chain reaction. RESULTS: In old rats, TLR-5 and -7 were decreased in peritoneal fluid, whereas TLR 4/6/9 and Syk were increased in the spleen (p < 0.05). In young rats, TLR 2/4, dectin-1, and Trem-1 were increased in peritoneal fluid and decreased in the spleen (p < 0.05), but TLR 1/3/7/9/10 and Syk were vice versa (p < 0.05). DISCUSSION: Several parameters related to innate immunity may change with aging. CONCLUSION: Different expressions of mRNA for several PRRs are suggesting changes in innate immune responses in association with aging.


Subject(s)
Ascitic Fluid/immunology , Immunity, Innate , Spleen/immunology , Aging/immunology , Animals , Lectins, C-Type/genetics , Lectins, C-Type/physiology , Male , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Receptors, Pattern Recognition/physiology , Toll-Like Receptors/genetics , Toll-Like Receptors/physiology , Triggering Receptor Expressed on Myeloid Cells-1/genetics , Triggering Receptor Expressed on Myeloid Cells-1/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...